hepat
b
viru
hbv
infect
major
public
health
problem
throughout
world
especi
east
asia
africa
estim
two
billion
peopl
roughli
world
popul
infect
hbv
million
patient
chronic
hepat
b
chb
liaw
chu
year
death
caus
hbv
infect
associ
liver
diseas
lozano
et
al
includ
hepat
decompens
cirrhosi
hepatocellular
carcinoma
individu
higher
risk
hbv
relat
diseas
lee
et
al
although
effici
prophylact
vaccin
develop
prevent
hbv
infect
still
cure
exist
infect
current
clinic
appli
therapeut
agent
chb
mainli
immunomodul
nucleosidenucleotid
analogu
use
either
separ
combin
yuen
lai
papatheodoridi
et
al
scaglion
lok
trepo
et
al
interferon
alpha
immunodul
control
hbv
infect
stimul
cellular
antivir
cytokin
express
inhibit
viral
replic
enhanc
host
immun
respons
elimin
hepatocyt
yuen
lai
howev
poor
respons
chb
high
commerci
cost
variou
advers
effect
ae
limit
wide
clinic
applic
drug
multipl
nucleosid
lamivudin
entecavir
telbivudin
nucleotid
analogu
adefovir
tenofovir
approv
clinic
applic
liaw
chu
oral
antivir
agent
mainli
target
hbv
polymeras
revers
transcriptas
rapidli
potent
inhibit
activ
although
nucleosidenucleotid
analogu
fewer
ae
fail
erad
hbv
coval
close
circular
dna
cccdna
nuclei
infect
hepatocyt
result
viral
relaps
stop
medic
yuen
lai
trepo
et
al
addit
develop
drug
resist
therapi
also
limit
effect
applic
nucleosidenucleotid
analogu
recent
drug
entecavir
tenofovir
observ
induc
low
level
drug
resist
applic
may
still
induc
expans
hbv
strain
mutat
resist
drug
trepo
et
al
thu
develop
novel
effect
therapeut
approach
agent
necessari
step
hbv
infect
selenium
se
essenti
trace
miner
anim
human
addit
antioxid
activ
se
also
shown
anticanc
properti
rayman
se
function
either
inorgan
form
sodium
selenit
sodium
selen
organ
form
amino
acid
selenocystein
sec
selenomethionin
semet
multipl
selenomolecl
intermediari
metabolit
papp
et
al
upon
absorpt
inorgan
salt
oxid
form
selenit
selen
reduc
selenid
use
reduc
equival
reduc
glutathion
reduc
nicotinamid
adenin
dinucleotid
phosphat
nadph
zeng
comb
storag
mechan
semet
replac
normal
methionin
protein
synthesi
releas
revers
normal
metabol
process
necessari
schrauzer
sec
probabl
abund
biolog
activ
form
selenium
vivo
special
incorpor
selenoprotein
amino
acid
encod
uga
codon
metani
hilvert
importantli
sec
might
play
import
biolog
role
vivo
identifi
human
selenoprotein
shown
enzymat
redox
function
catalyt
antioxid
activ
confer
sec
kryukov
et
al
papp
et
al
besid
biolog
function
describ
se
also
involv
occurr
virul
diseas
progress
viral
infect
rayman
moghadaszadeh
begg
rna
virus
includ
coxsackieviru
caus
keshan
diseas
human
immunodefici
viru
hiv
influenza
viru
sar
coronaviru
ebola
viru
absenc
se
caus
accumul
mutat
genom
lead
chang
genet
structur
beck
et
al
harthil
viral
glutathion
peroxidas
vgpx
selenoprotein
antioxid
activ
found
encod
rna
viru
hiv
hepat
c
viru
zhang
et
al
cell
vgpx
inhibit
apoptosi
host
respons
infect
promot
viral
replic
papp
et
al
date
report
describ
possibl
relev
se
hbv
infect
yu
et
al
khan
et
al
direct
evid
still
lack
underli
mechan
remain
elucid
present
studi
hepatoma
cell
transfect
two
differ
hbv
plasmid
util
order
investig
effect
hbv
data
clearli
clarifi
applic
inhibit
hbsaghbeag
express
hbv
transcript
genom
replic
examin
model
first
report
direct
evid
confirm
suppress
effect
se
hbv
replic
human
hepatoma
cell
line
obtain
china
center
type
cultur
collect
cctcc
maintain
dulbecco
modifi
eagl
medium
supplement
vv
fetal
bovin
serum
mgml
penicillin
streptomycin
gibco
life
technolog
incub
deriv
cell
stabli
transfect
construct
contain
two
dimer
hbv
genom
genbank
access
also
ad
maintain
cell
line
plasmid
hbv
construct
contain
copi
hbv
genom
subtyp
ayw
driven
human
cytomegaloviru
hcmv
immedi
earli
protein
promot
nassal
kind
gift
dr
michael
nassal
anoth
hbv
construct
gener
insert
copi
hbv
genom
subtyp
adw
start
promot
region
doitsh
shaul
kind
gift
dr
yosef
shaul
studi
viral
replic
plasmid
transfect
cell
cm
plate
use
invitrogen
waltham
accord
manufactur
instruct
cultur
hr
transfect
hr
medium
replac
fresh
medium
nm
entecavir
etv
sigma
aldrich
st
louiu
mo
dissolv
steril
salin
pb
treatment
start
day
defin
day
sampl
collect
indic
time
point
cell
cellswel
cultur
plate
indic
concentr
ad
cultur
h
later
cell
harvest
indic
time
point
assay
colorimetri
cell
count
dojindo
laboratori
quantifi
hbsag
hbeag
product
supernat
cell
indic
treatment
collect
test
presenc
hbsag
hbeag
use
commerci
immunosorb
assay
elisa
kit
kehua
result
normal
pb
control
sampl
cell
wash
twice
pb
homogen
trizol
invitrogen
total
rna
isol
accord
manufactur
protocol
potenti
dna
contamin
extract
elimin
recombin
dnase
takara
sampl
incub
min
denatur
rna
electrophores
hr
v
wv
agaros
gel
presenc
formaldehyd
describ
previous
tian
et
al
resolv
rna
blot
onto
posit
charg
nylon
membran
hybrid
probe
specif
hbv
genom
visual
imag
obtain
use
cyclon
plu
storag
phosphor
system
perkinelm
waltham
cell
level
northern
blot
assay
normal
rna
intracellular
viral
core
dna
isol
use
method
describ
previous
feng
et
al
briefli
cell
lyse
either
ml
cell
per
cm
plate
ml
cell
per
cm
plate
lysi
buffer
mm
ph
mm
nacl
remov
cell
debri
centrifug
supernat
treat
u
dnase
takara
rnase
takara
incub
hr
presenc
mm
complet
digest
dna
rna
core
particl
degrad
mm
proteinas
k
tiangen
encapsid
dna
extract
phenol
chloroform
precipit
ethanol
follow
separ
agaros
gel
wv
isol
encapsid
hbv
dna
blot
onto
posit
charg
nylon
membran
millipor
hybrid
probe
use
northern
blot
assay
final
signal
visual
use
cyclon
plu
storag
phosphor
system
perkin
elmer
cell
level
southern
blot
assay
normal
protein
level
quantit
polymeras
chain
reaction
perform
sybr
premix
ex
taq
ii
takara
use
lightcycl
pcr
system
roch
penzberg
germani
hbv
genom
sequenc
genebank
access
amplifi
primer
aat
cgc
cag
tca
gga
agc
agg
gaa
ata
cag
genebank
access
serv
intern
refer
amplifi
primer
gta
cgt
tgc
tat
cca
ctt
aat
gtc
acg
cac
cycl
program
run
min
follow
cycl
sec
sec
sec
result
toxic
assay
elisa
shown
mean
standard
error
least
three
independ
experi
statist
differ
analyz
use
unpair
student
test
differ
consid
statist
signific
p
result
southern
northern
blot
assay
repres
imag
select
least
three
independ
experi
elimin
possibl
observ
influenc
hbv
replic
caus
cytotox
influenc
prolifer
examin
use
assay
signific
toxic
cell
observ
concentr
wherea
treatment
beyond
concentr
display
inhibit
growth
manner
fig
cell
show
greater
toler
treatment
treatment
three
day
five
day
chang
growth
compar
control
beyond
concentr
cell
number
decreas
gradual
indic
cytotox
fig
cell
type
signific
differ
observ
treatment
period
safe
concentr
howev
number
viabl
cell
obvious
decreas
treatment
period
beyond
safe
concentr
fig
b
declin
cell
growth
one
three
five
day
rel
consist
fig
treat
five
day
show
dramat
decreas
cell
growth
compar
day
one
three
fig
henc
show
signific
cytotox
either
cell
type
set
maximum
concentr
treatment
subsequ
experi
studi
effect
hbv
viral
protein
product
cell
hbv
cell
treat
four
concentr
investig
cytotox
fig
pb
nm
etv
use
control
three
day
supernat
cultur
collect
hbsag
hbeag
express
measur
elisa
enough
caus
signific
reduct
hbsag
hbeag
express
compar
control
examin
concentr
inhibit
hbv
antigen
product
manner
fig
b
cell
transfect
hbv
plasmid
fail
decreas
hbsag
hbeag
level
suppress
observ
start
fig
viral
antigen
hbv
cell
show
even
stronger
resist
hbsag
hbeag
level
start
declin
declin
enhanc
treatment
fig
f
next
fix
concentr
use
assess
viral
antigen
express
time
cours
cell
show
signific
inhibit
hbv
antigen
express
day
repress
effect
increas
time
fig
b
final
assess
day
day
treatment
caus
reduct
product
hbsag
hbeag
respect
similar
suppress
enhanc
also
observ
hbv
cell
maximum
decreas
viral
antigen
level
also
occur
day
compar
control
treatment
cell
transfect
hbv
plasmid
produc
drop
hbsag
level
fig
e
respect
drop
hbeag
level
respect
fig
f
obviou
decreas
hbv
cell
day
time
point
hbeag
alreadi
significantli
suppress
hbv
cell
fig
notabl
etv
treatment
affect
viral
antigen
product
model
fig
hbsag
hbeag
product
press
mrna
precor
mrna
level
variou
hbv
mrna
analyz
hbv
cell
presenc
four
concentr
use
concentr
analyz
differ
time
point
hbv
rna
examin
model
decreas
treatment
slight
differ
cell
obviou
effect
viral
transcript
dramat
decreas
hbv
rna
level
decreas
treatment
fig
concentr
fix
progress
repress
hbv
rna
level
cell
occur
line
length
treatment
start
day
fig
moreov
viral
transcript
level
quantifi
use
qpcr
host
gene
chosen
intern
refer
result
qpcr
fig
consist
northern
blot
assay
fig
viral
mrna
inhibit
treatment
manner
reduc
presenc
four
day
cell
transfect
plasmid
suppress
viral
mrna
fig
addit
percept
repress
hbv
transcript
observ
day
treatment
also
occur
manner
fig
suppress
hbv
transcript
also
occur
cell
transfect
plasmid
shown
figur
suppress
evid
littl
progress
manner
treatment
caus
dramat
suppress
hbv
rna
day
howev
suppress
effect
clear
two
model
probabl
rna
amount
alreadi
drop
low
level
therefor
effect
subsequ
examin
time
point
less
obviou
fig
model
nm
etv
treatment
produc
effect
hbv
transcript
level
specif
inhibit
activ
jone
et
al
intracellular
viral
core
protein
also
determin
use
western
blot
assay
three
model
host
protein
intern
refer
core
protein
level
decreas
gradual
follow
treatment
manner
wherea
level
remain
unchang
fig
nm
etv
treatment
could
affect
core
express
model
fig
result
indic
influenc
specif
hbv
transcript
express
fact
repress
hbv
protein
synthesi
transcript
manner
prompt
us
investig
whether
also
influenc
hbv
dna
level
address
issu
encapsid
hbv
dna
extract
cell
treat
etv
analyz
southern
blot
assay
model
viral
nucleic
acid
bare
detect
nm
etv
treatment
three
day
fig
c
e
four
day
fig
f
consid
etv
hardli
chang
level
viral
protein
rna
dramat
inhibit
hbv
dna
consist
specif
suppress
hbv
replic
previou
studi
also
report
nm
etv
suffici
reduc
hbv
dna
level
bader
korba
agreement
result
gener
treatment
display
clear
suppress
hbv
dna
level
model
fig
although
slight
differ
still
exist
differ
model
treatment
result
obviou
repress
hbv
dna
cell
clear
dna
declin
occur
treatment
day
well
day
hbv
dna
level
reduc
progress
line
increas
concentr
exposur
time
fig
b
transfect
plasmid
treatment
result
inhibit
hbv
dna
start
reduct
hbv
dna
also
observ
less
obviou
possibl
due
profound
decreas
viral
dna
level
observ
earli
day
fig
cell
decreas
induc
weaker
two
test
model
reduct
hbv
dna
visibl
treatment
day
fig
day
fig
investig
activ
compar
clinic
appli
nucleo
ide
analog
includ
lamivudin
entecavir
etv
adefovir
ade
three
six
day
treatment
singl
combin
drug
encapsid
hbv
dna
level
quantifi
use
qpcr
result
show
three
day
treatment
nm
lamivudin
nm
entecavir
adefovir
reduc
viral
dna
level
respect
fig
day
inhibitori
effect
dna
level
enhanc
lamivudin
treat
cell
hbv
dna
level
decreas
respect
fig
moreov
combin
drug
treatment
dramat
enhanc
inhibitori
effect
hbv
dna
replic
day
plu
lamivudin
entecavir
adefovir
reduc
encapsid
hbv
dna
level
respect
fig
hepat
b
viru
prototyp
member
hepadnavirida
famili
replic
uniqu
revers
transcript
mechan
nassal
infecti
virion
contain
genom
kb
relax
circular
dna
rc
dna
transform
cccdna
host
cell
nucleu
beck
nassal
two
subset
viral
rna
name
subgenom
rna
press
mrna
hbx
mrna
pregenom
rna
pgrna
precor
mrna
transcrib
cellular
rna
polymeras
ii
use
cccdna
templat
beck
nassal
although
se
report
influenc
multipl
viru
infect
rayman
beck
et
al
beck
harthil
limit
inform
avail
whether
effect
hbv
infect
one
studi
shown
significantli
lower
concentr
se
serum
patient
hbv
infect
compar
healthi
individu
khan
et
al
moreov
accord
investig
individu
qidong
china
se
supplement
via
tabl
salt
significantli
reduc
incid
primari
liver
cancer
yu
et
al
howev
none
avail
studi
show
solid
evid
relationship
se
hbv
replic
present
studi
first
demonstr
direct
inhibitori
effect
hbv
cellular
level
use
differ
hbv
cell
model
hbeag
hbsag
secret
serum
hepatocyt
appear
differ
phase
infect
differ
clinic
implic
papatheodoridi
et
al
trepo
et
al
hbsag
hallmark
infect
although
hbeag
usual
associ
high
level
viral
replic
although
nucleosidenucleotid
analogu
inhibit
hbv
replic
result
obviou
reduct
hbv
dna
hbeag
level
serum
littl
impact
hbsag
secret
scaglion
lok
present
studi
reveal
evid
declin
hbsaghbeag
level
treatment
three
test
model
fig
howev
must
note
driven
construct
allow
synthesi
hbeag
lack
intact
precor
region
end
nassal
hbeag
detect
transfect
plasmid
might
core
protein
due
antibodi
cross
reactiv
intracellular
core
protein
level
also
determin
model
result
show
treatment
obvious
reduc
core
express
host
cell
intern
refer
protein
fig
result
prompt
us
investig
reason
viral
antigen
decreas
hbv
transcript
level
mani
publish
research
articl
reveal
se
regul
variou
physiolog
activ
cell
gene
transcript
signal
transduct
cell
apoptosi
mckenzi
et
al
zeng
sund
rain
shown
northern
blot
assay
qpcr
inhibit
hbv
transcript
manner
fig
hbv
mrna
synthesi
primarili
depend
rna
polymeras
ii
transcript
regul
system
host
cell
levrero
et
al
quasdorff
protzer
like
follow
cellular
factor
possibl
involv
observ
suppress
first
potenti
candid
treatment
may
activ
promot
express
phosphoryl
multipl
site
smith
et
al
homologu
report
repress
activ
hbv
promot
enhanc
lee
et
al
buhlmann
et
al
henc
possibl
intermediari
hbv
transcript
second
possibl
factor
specif
protein
bind
dna
element
regul
wide
varieti
gene
mammalian
cell
chu
least
three
bind
site
identifi
hbv
genom
activ
transcript
hbv
gene
bind
site
quasdorff
protzer
se
demonstr
decreas
express
activ
husbeck
et
al
prevent
activ
hbv
gene
therefor
se
like
affect
hbv
transcript
complic
regulatori
network
final
factor
hbx
encod
hbv
genom
multifunct
viral
protein
broadli
involv
transcript
signal
transduct
cell
cycl
progress
apoptosi
genet
stabil
oncogenesi
interact
bouchard
schneider
tang
et
al
ng
lee
motavaf
et
al
tang
et
al
report
hbv
transcript
replic
affect
simultan
hbx
transcript
activ
hbx
may
critic
augment
effect
hbv
replic
tang
et
al
hbx
also
induc
cytosol
calcium
elev
viral
dna
replic
viral
transcript
interact
famili
member
geng
et
al
activ
cytosol
tyrosin
bouchard
et
al
although
se
prove
direct
effect
hbx
demonstr
affect
host
factor
includ
nuclear
result
signific
decreas
cellular
calcium
releas
uguz
naziroglu
thu
hbx
anoth
suspect
viral
factor
possibl
mediat
inhibit
hbv
transcript
replic
southern
blot
assay
shown
figur
show
evid
declin
hbv
dna
level
treatment
three
test
model
howev
dissimilar
suppress
three
model
possibl
due
differ
cell
line
system
progress
reduct
hbv
dna
display
similar
trend
decreas
hbv
mrna
indic
one
potenti
mechan
suppress
hbv
replic
inhibit
viral
transcript
addit
suppress
viral
transcript
se
may
also
inhibit
hbv
replic
cytosol
calcium
releas
relat
hbx
host
cell
bouchard
et
al
geng
et
al
hypothesi
selenit
inhibit
hbv
transcript
replic
via
host
viral
factor
still
need
verifi
potenti
involv
factor
need
identifi
experi
addit
efficaci
quantit
compar
nucleo
ide
analogu
use
qpcr
alon
combin
fig
day
spite
higher
treat
concert
exhibit
similar
efficaci
drug
less
potent
inhibit
hbv
replic
compar
test
drug
probabl
due
indirect
effect
viral
polymeras
howev
nucleo
ide
drug
affect
differ
factor
replic
cycl
hbv
combin
show
efficaci
either
treatment
alon
fig
conclus
data
date
first
time
directli
prove
inhibit
hbsaghbeag
express
hbv
transcript
well
viral
genom
replic
hbv
suppress
effect
made
se
potenti
therapeut
medic
control
hbv
infect
zc
xz
perform
experi
zc
fz
kh
design
research
gs
gw
ws
yh
xt
provid
experiment
support
zc
fz
draft
manuscript
author
read
approv
final
manuscript
submiss
